Aptus Pharma Q1 FY27: Revenue ₹32.20 Cr, PAT ₹2.87 Cr
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
Guidance rank: #39 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Aptus Pharma Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) - Revenue for H1 FY26: ₹14.38 crore, up 123.9% QoQ from H2 FY25 (Page 23) - Revenue for FY26: ₹4 Quarter (H2 FY26) Financials (Page 23): - EBITDA: ₹4.49 crore, up 56.3% YoY from ₹2.88 crore - EBITDA Margin: 14.0%, down from 19.4% YoY - PAT: ₹2.87 crore, up 60.1% YoY from ₹1.79 crore
From Aptus Pharma Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23)
- Revenue for H1 FY26: ₹14.38 crore, up 123.9% QoQ from H2 FY25 (Page 23)
- Revenue for FY26: ₹46.57 crore, up 89.7% YoY from ₹24.56 crore in FY25 (Page 26)
- Outlook: Strategic growth roadmap targets Pan-India presence by March 2029 and global expansion by March 2028 across Asia, Africa, and Latin America (Page 28)
2 more points from Aptus Pharma Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Aptus Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Aptus Pharma follows an asset-light contract manufacturing model and does not own manufacturing facilities, relying on WHO-GMP-certified partners (Page 14).
- The company has formal loan and licence agreements with two manufacturing units in Gujarat (Page 14).
- Strategic Growth Roadmap aims for own manufacturing to constitute 20% by March 2028, strengthening quality control and supply-chain (Page 28).
2 more points from Aptus Pharma Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Aptus Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Aptus Pharma Ltd said on order book & pipeline — free account, 30 seconds.
Continue your research
What Aptus Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Aptus Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Aptus Pharma Ltd Q1 FY27 results?
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) - Revenue for H1 FY26: ₹14.38 crore, up 123.9% QoQ from H2 FY25 (Page 23) - Revenue for FY26: ₹4 Quarter (H2 FY26) Financials (Page 23): - EBITDA: ₹4.49 crore, up 56.3% YoY from ₹2.88 crore - EBITDA Margin: 14.0%, down from 19.4% YoY - PAT: ₹2.87 crore, up 60.1% YoY from ₹1.79 crore
What is Aptus Pharma Ltd share price analysis?
Aptus Pharma Ltd currently shows a neutral. The stock trades at a P/E of 131.2 with a market cap of ₹606 Cr. Investors should review the full earnings analysis for detailed insights.
Is Aptus Pharma Ltd planning capital expenditure?
Aptus Pharma follows an asset-light contract manufacturing model and does not own manufacturing facilities, relying on WHO-GMP-certified partners (Page 14).
Keep Aptus Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
